UBS Group AG Boosts Stock Position in Beta Bionics, Inc. $BBNX

UBS Group AG raised its holdings in Beta Bionics, Inc. (NASDAQ:BBNX) by 96.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,438 shares of the company’s stock after buying an additional 123,533 shares during the period. UBS Group AG owned about 0.57% of Beta Bionics worth $7,661,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Beta Bionics during the 1st quarter worth about $95,000. Goldman Sachs Group Inc. purchased a new stake in Beta Bionics during the first quarter worth approximately $715,000. Woodline Partners LP purchased a new stake in Beta Bionics during the first quarter worth approximately $1,530,000. Strs Ohio acquired a new position in Beta Bionics in the first quarter valued at approximately $29,000. Finally, Rhumbline Advisers acquired a new position in Beta Bionics in the first quarter valued at approximately $158,000.

Beta Bionics Stock Down 0.6%

NASDAQ BBNX opened at $9.40 on Tuesday. The firm has a market cap of $418.86 million, a P/E ratio of -6.23 and a beta of 3.29. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The business’s 50-day moving average price is $10.61 and its 200 day moving average price is $18.61.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The company had revenue of $27.63 million during the quarter. As a group, analysts anticipate that Beta Bionics, Inc. will post -2.19 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Truist Financial cut their price objective on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Bank of America dropped their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday. Leerink Partners cut their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. TD Cowen assumed coverage on shares of Beta Bionics in a research report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target for the company. Finally, Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.